Edgar Filing: Cara Therapeutics, Inc. - Form 4

| Cara Therap Form 4 | | | | | | | | | | | |
|---|--|--|--|---|------------|------------------------------|-------------------------|--|--|------------------------------------|--|
| July 06, 201 | ЛЛ | | | | | | | | OMB AF | PROVAL | |
| Check th | UNITEL | Washington, D.C. 20549 | | | | | | | | 3235-0287 | |
| Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may cont <i>See</i> Instr 1(b). | ger 5 16. 5 5 5 5 5 5 5 5 5 5 5 5 5 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section | | | | | | | burden hou response | Estimated average burden hours per | |
| (Print or Type I | Responses) | | | | | | | | | | |
| Menzaghi Frederique Ph.D. Symbol | | | | er Name and Ticker or Trading herapeutics, Inc. [CARA] | | | | 5. Relationship of Reporting Person(s) to Issuer | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Check | | | | | k all applicable |) | | |
| | | | | (Month/Day/Year) 07/01/2015 | | | | Director 10% Owner Officer (give title Other (specify below) below) VP-Research & Development | | | |
| | | | | endment, Date Original onth/Day/Year) | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | | |
| SHELTON, | , CT 06484 | | | | | | | Form filed by M Person | Iore than One Re | porting | |
| (City) | (State) | (Zip) | Tabl | e I - Non-D | erivative | Secur | ities Acq | uired, Disposed of | , or Beneficial | ly Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Da (Month/Day/Yea | r) Executio any | on Date, if | 3. Transactic Code (Instr. 8) Code V | (Instr. 3, | ispose 4 and (A) or | d of (D) 5) Price | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Indirect Beneficial | |
| Common Stock | 07/01/2015 | | | S <u>(1)</u> | 7,000 | D | \$ 12.22 (2) | 173,000 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transacti Code (Instr. 8) | 5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | Date | Amou Unde Secur | le and int of rlying ities . 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr |
|---|---|---|---------------------------------------|---|---------------------|--------------------|-----------------------|---|---|--|
| | | | Code V | . , | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--|---------------|-----------|---------------------------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| Menzaghi Frederique Ph.D. C/O CARA THERAPEUTICS, INC. 1 PARROTT DRIVE SHELTON, CT 06484 | | | VP-Research & Development | | | | |
| Signatures | | | | | | | |
| /s/Darren DeStefano, Attorney-in-Fact | 07/0 | 06/2015 | | | | | |
| **Signature of Reporting Person |] | Date | | | | | |

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2015.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.00 - \$12.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities

(2) and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: Cara Therapeutics, Inc. - Form 4